New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance.
Macrolide-resistant bacteria can be classified as inducibly resistant or constitutively resistant. Inducibly resistant bacteria are resistant to 14-membered macrolides, such as erythromycin and clarithromycin (A-56268), but are susceptible to the 16-membered macrolides, such as tylosin and spiramycin, as well as to clindamycin. Constitutively resistant bacteria are resistant to macrolide-lincosamide-streptogramin B antibiotics. In this study, the MICs of several erythromycin and clarithromycin analogs against macrolide-susceptible and macrolide-resistant Streptococcus pyogenes strains were determined. Four 11,12-carbamate analogs of clarithromycin had lower MICs than erythromycin did against S. pyogenes with the inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. Five 11,12-carbonate analogs of erythromycin with modifications at the 4" position of cladinose had lower MICs than did erythromycin against S. pyogenes with the constitutive type of resistance, and one of these compounds, which had a naphthyl-glycyl substitution at the 4" position, had a lower MIC than erythromycin against both the inducibly resistant and constitutively resistant strains. Two analogs of erythromycin with a modification on the 4" position of cladinose had lower MICs than erythromycin did against the constitutively resistant organisms but not against the inducibly resistant organisms. Thus, 14-membered macrolides can be modified so as to confer a low MIC when tested in vitro.
Fernandes
P B
PB
Anti-Infective Research, Abbott Laboratories, Abbott Park, Illinois 60064.
Baker
W R
WR
Freiberg
L A
LA
Hardy
D J
DJ
McDonald
E J
EJ
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017291:Clarithromycin; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D007933:Leucomycins / Q000494:pharmacology; D055231:Lincosamides; D018942:Macrolides; D015394:Molecular Structure; D013297:Streptococcus pyogenes / Q000187:drug effects* / Q000378:metabolism; D014769:Virginiamycin / Q000494:pharmacology*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D007933:Leucomycins; D055231:Lincosamides; D018942:Macrolides; D014769:Virginiamycin; D004917:Erythromycin; D017291:Clarithromycin